Moderna (MRNA) Q1 FY25 earnings call

Moderna reported Q1 FY25 results marked by significant cost reductions across R&D, SG&A, and cost of sales, driving an improved net loss despite lower seasonal revenues. The company expanded its oncology pipeline with a new checkpoint program and progressed its late-stage vaccine candidates, though regulatory timelines for some combination vaccines have shifted. Management remains committed to achieving cash breakeven by 2028 through continued financial discipline and strategic pipeline investments.